Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Inflammatory Bowel Diseases

Free Subscription 03.11.2025 1 Aliment Pharmacol Ther 2 Am J Gastroenterol 2 BMC Gastroenterol 1 Clin Gastroenterol Hepatol 1 Dis Colon Rectum 1 Gastroenterology 1 Hum Pathol 7 Inflamm Bowel Dis 3 J Crohns Colitis 3 Lancet Gastroenterol Hepatol 1 Mediators Inflamm 1 Minerva Gastroenterol (Torino) 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. DERKS MEW, Te Groen M, Derikx LAAP, Nagtegaal ID, et al
   High Risk of Colorectal Cancer After High-Grade Dysplasia in Inflammatory Bowel Disease Patients.
   Aliment Pharmacol Ther. 2025 Oct 24. doi: 10.1111/apt.70429.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

2. CALDERA F, Hayney MS, Strople JA, Kastl AJ, et al
   Low Sensitivity of Commercial Assays for Varicella Zoster Virus Seropositivity in Pediatric Patients with Inflammatory Bowel Disease.
   Am J Gastroenterol. 2025 Oct 28. doi: 10.14309/ajg.0000000000003819.
   PubMed         Abstract available
   
   
3. PARIGI TL, Nardone OM, Lisa M, Massimino L, et al
   The impact of E-Cigarettes and Heat-Not-Burn Tobacco on Postoperative Recurrence of Crohn's Disease: A Multicenter International Study.
   Am J Gastroenterol. 2025 Oct 24. doi: 10.14309/ajg.0000000000003810.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

4. TU T, Zhuang X, Qiu Y, Li M, et al
   Histological remission as a reliable predictor of clinical outcomes in patients with ulcerative colitis after conventional therapy: a 5-year analysis.
   BMC Gastroenterol. 2025;25:771.
   PubMed         Abstract available
   
   
5. KOJIMA M, Miyake T, Bamba S, Tani S, et al
   Risk factors for surgical recurrence and the preventive effect of endoscopic balloon dilatation in postoperative patients with Crohn 's disease.
   BMC Gastroenterol. 2025;25:764.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

6. FERNANDES RG, Kim DH, Ruddick-Collins L, Vasudevan A, et al
   Acute severe ulcerative colitis patients from Asia have lower colectomy risk than patients from Australasia.
   Clin Gastroenterol Hepatol. 2025 Oct 29:S1542-3565(25)00927.
   PubMed         Abstract available
   
   

   
   Dis Colon Rectum

7. ZUCKERMAN J, de Buck van Overstraeten A, Melmed GY, Mustain WC, et al
   Improvement in Functional Outcomes Following Ileal Pouch-Anal Anastomosis: Results from the United States Ileal Pouch-Anal Anastomosis Study.
   Dis Colon Rectum. 2025;68:1315-1326.
   PubMed         Abstract available
   
   

   
   Gastroenterology

8. TIAN Z, Huang Y
   Improving Precision in Crohn's Disease: Insights from the VCE Trial.
   Gastroenterology. 2025 Oct 29:S0016-5085(25)05894.
   PubMed        
   
   

   
   Hum Pathol

9. BAHCECI D, Choi WT
   Recent updates and debates on basal crypt dysplasia, serrated epithelial change, and p53 immunostaining in inflammatory bowel disease.
   Hum Pathol. 2025 Oct 24:105959. doi: 10.1016/j.humpath.2025.105959.
   PubMed         Abstract available
   
   

   
   Inflamm Bowel Dis

10. LIU EY, An A, Khan S, Battat R, et al
    The Impact of Endoscopic Healing on Disease-Related Outcomes in Patients With Ulcerative Proctitis.
    Inflamm Bowel Dis. 2025;31:2725-2734.
    PubMed         Abstract available
    
    
11. SCHREIBER S, Colombel JF, Hanauer SB, Sandborn WJ, et al
    Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies.
    Inflamm Bowel Dis. 2025;31:2714-2724.
    PubMed         Abstract available
    
    
12. TEICHERT C, Anjie SI, Stevens TW, Bahur B, et al
    Clinical Utility and Accuracy of Point-of-Care Testing for Anti-TNF Drug Monitoring and Loss of Response.
    Inflamm Bowel Dis. 2025;31:2886-2894.
    PubMed         Abstract available
    
    
13. GORDON M, Shaban N, Sinopoulou V, Vuyyuru S, et al
    Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions.
    Inflamm Bowel Dis. 2025;31:2798-2804.
    PubMed         Abstract available
    
    
14. MENDES-FRIAS A, Vieira MC, Araujo M, Duarte-Oliveira C, et al
    Branched-Chain Amino Acids Exacerbate Colitis Progression by Lowering Colonic Fumarate Levels.
    Inflamm Bowel Dis. 2025;31:2840-2852.
    PubMed         Abstract available
    
    
15. CEJUDO-GARCES A, Carda-Dieguez M, Navarro-Vicente F, Calatayud S, et al
    Characterization of Intestinal Mycobiome in Surgical Resections from Inflammatory Bowel Disease Patients: A Deeper Analysis in Complicated Crohn's Disease Phenotypes.
    Inflamm Bowel Dis. 2025 Oct 30:izaf178. doi: 10.1093.
    PubMed         Abstract available
    
    
16. LIU K, Wang J, Li J
    Comments on the Study of Colonic Taste Receptors, Fecal Amino Acids, and Ulcerative Colitis: Methodological Considerations for Enhanced Generalizability.
    Inflamm Bowel Dis. 2025 Oct 29:izaf237. doi: 10.1093.
    PubMed        
    
    

    
    J Crohns Colitis

17. CHATTO M, Alaskar D, Ma C, Yuan Y, et al
    Pharmacological management of upper gastrointestinal crohn's disease: A systematic review.
    J Crohns Colitis. 2025 Oct 28:jjaf187. doi: 10.1093.
    PubMed         Abstract available
    
    
18. PRUIJT MJ, Teichert C, De Voogd FA, Janssen RJ, et al
    Kinetics of Intestinal Ultrasound and Shear-wave Elastography to assess early response in Ulcerative Colitis Patients Treated with Filgotinib.
    J Crohns Colitis. 2025 Oct 28:jjaf185. doi: 10.1093.
    PubMed         Abstract available
    
    
19. FRANCISCO M, Alicia LG, Jose MB, Cristina RC, et al
    Therapeutic management and risk of colectomy in patients with acute severe ulcerative colitis and previous exposure to anti-TNF drugs: a comparative study of GETECCU.
    J Crohns Colitis. 2025 Oct 25:jjaf183. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Lancet Gastroenterol Hepatol

20. EGGERMONT E, Gecse K, Krugliak Cleveland N, Petersen F, et al
    Ulcerative colitis: moving beyond the mucosal dogma.
    Lancet Gastroenterol Hepatol. 2025 Oct 28:S2468-1253(25)00263.
    PubMed         Abstract available
    
    
21. HOIVIK ML
    Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced?
    Lancet Gastroenterol Hepatol. 2025 Oct 27:S2468-1253(25)00258.
    PubMed        
    
    
22. D'HAENS GR, Lowenberg M, Baert F, Bossuyt P, et al
    Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study.
    Lancet Gastroenterol Hepatol. 2025 Oct 27:S2468-1253(25)00233.
    PubMed         Abstract available
    
    

    
    Mediators Inflamm

23. RAHAMAN MM, Wangchuk P, Sarker S
    Targeting Interferon-Gamma (IFN-gamma)-Related Signalling Pathways in Inflammatory Bowel Disease: Emerging Inhibitors and Therapeutic Advances.
    Mediators Inflamm. 2025;2025:3181200.
    PubMed         Abstract available
    
    

    
    Minerva Gastroenterol (Torino)

24. NANDI N, Becq A, Michelon M, Sidhu R, et al
    The role of capsule endoscopy in Crohn's disease.
    Minerva Gastroenterol (Torino). 2025 Oct 29. doi: 10.23736/S2724-5985.25.03867.
    PubMed         Abstract available
    
    

    
    PLoS One

25. MADARAME A, Fukuzawa M, Uchida K, Ichimiya T, et al
    Significance of the drug-induced lymphocyte stimulation test for various oral mesalamines in ulcerative colitis with mesalamine intolerance.
    PLoS One. 2025;20:e0334969.
    PubMed         Abstract available
    
    
26. KUBESCH A, Lande R, Leutgob A, Farrag K, et al
    Sequencing Therapy for Optimal Response in Mirikizumab (STORM)-study: A tertiary referral center study on patients with therapy-refractory ulcerative colitis.
    PLoS One. 2025;20:e0334897.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.